Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480222 | 0.87 | POLB (0.57) | ENPP2MAPTMEN1KMT2AP2RX7 | |
| SCHEMBL5470893 | 0.83 | MAPT (0.47) | ENPP2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5479921 | 0.74 | P2RX7 (0.50) | P2RX7LMNA | |
| SCHEMBL5477807 | 0.73 | POLB (0.55) | ENPP2MEN1KMT2AP2RX7LMNA | |
| SCHEMBL5470632 | 0.72 | POLB (0.51) | MAPTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL4519320 | 0.71 | KMT2A (0.55) | MAPTMEN1KMT2AP2RX7SMN1; SMN2 | |
| SCHEMBL5475968 | 0.71 | POLB (0.50) | MAPTMEN1KMT2AP2RX7LMNA | |
| SCHEMBL5480340 | 0.70 | P2RX7 (0.49) | MEN1KMT2AP2RX7LMNAPOLB | |
| Hydrochloric Acid SCHEMBL5474134 | 0.69 | P2RX7 (0.45) | P2RX7LMNA | |
| SCHEMBL8114562 | 0.68 | KMT2A (1.00) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | ENPP2 368/4885MAPT 1199/4885MEN1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.